Revenue at Amgen continued to decline in the third quarter, but net income climbed nearly 6 percent while stock buybacks propelled earnings per share up 14 percent. Revenue fell 3 percent to $5.7 billion, as biosimilar and generic competitors continued to eat into the Thousand Oaks biotech giant’s core products, such as white blood cell…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
